Lixte Biotechnology Holdings, Inc.
LIXT
$1.26
$0.000.00%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -34.00% | -30.29% | -35.74% | -28.22% | -25.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -40.20% | -3.99% | -39.57% | -29.43% | -37.16% |
| Operating Income | 40.20% | 3.99% | 39.57% | 29.43% | 37.16% |
| Income Before Tax | 40.16% | 3.22% | 39.41% | 28.98% | 36.72% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.16% | 3.22% | 39.41% | 28.98% | 36.72% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.16% | 3.22% | 39.41% | 28.98% | 36.72% |
| EBIT | 40.20% | 3.99% | 39.57% | 29.43% | 37.16% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 40.07% | 10.71% | 55.12% | 47.43% | 53.22% |
| Normalized Basic EPS | 40.08% | 10.72% | 55.12% | 47.43% | 53.21% |
| EPS Diluted | 40.07% | 10.71% | 55.12% | 47.43% | 53.22% |
| Normalized Diluted EPS | 40.08% | 10.72% | 55.12% | 47.43% | 53.21% |
| Average Basic Shares Outstanding | -0.16% | 8.41% | 35.01% | 35.09% | 35.27% |
| Average Diluted Shares Outstanding | -0.16% | 8.41% | 35.01% | 35.09% | 35.27% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |